Trial Profile
Phase I Trial of ECI301 in Combination With Radiation in Patients With Advanced or Metastatic Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 31 Dec 2021
Price :
$35
*
At a glance
- Drugs ECI 301 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 01 Apr 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 08 Apr 2012 Additional lead trial centre and investigator identified as reported by University Hospital Medical Information Network - Japan.
- 08 Apr 2012 Additional trial location (Japan) identified as reported by University Hospital Medical Information Network - Japan.